Daiichi Sankyo Co. Ltd. plans to more than double its U.S. sales staff in preparation for new drugs expected to come to market. According to a company statement, Daiichi Sankyo said it was also looking to expand its business through strategic investments, boost its European sales force and set up a new sales subsidiary in India. U.S. medical representatives will be approximately 2,300 by the end of March 2010, up from 900. Sales staff at another U.S. unit will rise to 350 from 50. “The e...